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A B S T R A C T
Background
The use of botulinum toxin as an investigative and treatment modality for strabismus is well reported in the medical literature. However,
it is unclear how effective it is in comparison to other treatment options for strabismus.
Objectives
The primary objective was to examine the efficacy of botulinum toxin therapy in the treatment of strabismus compared with alternative
conservative or surgical treatment options. This review sought to ascertain those types of strabismus that particularly benefit from the
use of botulinum toxin as a treatment option (such as small angle strabismus or strabismus with binocular potential, i.e. the potential
to use both eyes together as a pair). The secondary objectives were to investigate the dose effect and complication rates associated with
botulinum toxin.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 6), Ovid MEDLINE, Ovid
MEDLINE In-Process andOtherNon-IndexedCitations,OvidMEDLINEDaily,OvidOLDMEDLINE (January 1946 to July 2016),
Embase (January 1980 to July 2016), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to July
2016), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov), and the World Health
Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en).We did not use any date
or language restrictions in the electronic searches for trials. We last searched the electronic databases on 11 July 2016. We handsearched
the British and Irish Orthoptic Journal, Australian Orthoptic Journal, proceedings of the European Strabismological Association (ESA),
International Strabismological Association (ISA) and International Orthoptic Association (IOA) (www.liv.ac.uk/orthoptics/research/
search.htm) and American Academy of Paediatric Ophthalmology and Strabismus meetings (AAPOS). We contacted researchers who
are active in this field for information about further published or unpublished studies.
Selection criteria
We included randomised controlled trials (RCTS) of any use of botulinum toxin treatment for strabismus.
Data collection and analysis
Two review authors independently selected studies and extracted data. We used standard methods expected by Cochrane and assessed
the certainty of the evidence using GRADE. We defined ocular alignment as an angle of deviation of less than or equal to 10 prism
dioptres.
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Main results
Six RCTs were eligible for inclusion. We judged the included studies as at a mixture of low, unclear and high risk of bias. We did not
consider any of the included studies as at low risk of bias for all domains.
Two trials conducted in Spain (102 people, number of eyes not specified) compared botulinum toxin with surgery in children that
required retreatment for acquired or infantile esotropia. These two studies provided low-certainty evidence that children who received
botulinum toxin may have a similar or slightly reduced chance of achieving ocular alignment (pooled risk ratio (RR) 0.91, 95%
confidence interval (CI) 0.71 to 1.16), binocular single vision (RR 0.88, 95% CI 0.63 to 1.23), sensory fusion (RR 0.88, 95% CI
0.63 to 1.23) and stereopsis (RR 0.86, 95% CI 0.59 to 1.25) compared with children who received surgery. One trial from Canada
compared botulinum toxin with surgery in 30 adults (30 eyes) with horizontal strabismus and reported a reduced chance of ocular
alignment with botulinum toxin (RR 0.38, 95% CI 0.17 to 0.85; low-certainty evidence).
One trial in the UK suggested that botulinum toxin may result in a similar or slightly improved chance of ocular alignment in people
with acute onset sixth nerve palsy compared with observation (RR 1.19, 95% CI 0.96 to 1.48; 47 participants, low-certainty evidence).
Very low-certainty evidence from one trial from Brazil suggested that adjuvant botulinum toxin in strabismus surgery may increase the
chances of ocular alignment compared with strabismus surgery alone (RR 1.83, 95% CI 0.41 to 8.11; 23 participants).
One trial from China of 47 participants (94 eyes) suggested that people receiving botulinum toxin combined with sodium hyaluronate
may have a similar or slightly reduced chance of achieving ocular alignment compared with botulinum toxin alone (RR 0.81, 95% CI
0.36 to 1.82; low-certainty evidence).
Reported complications in people given botulinum toxin in the included trials included ptosis (range 9% to 41.66%) and vertical devi-
ation (range 8.3% to 18.51%). Ptosis occurred less frequently when treated with botulinum toxin combined with sodium hyaluronate
compared to botulinum toxin alone.
Authors’ conclusions
Most published literature on the use of botulinum toxin in the treatment of strabismus consists of retrospective studies, cohort studies
or case reviews. Although these provide useful descriptive information, clarification is required as to the effective use of botulinum toxin
as an independent treatment modality. Six RCTs on the therapeutic use of botulinum toxin in strabismus, graded as low and very low-
certainty evidence, have shown varying responses. These include a lack of evidence for effect of botulinum toxin on reducing visual
symptoms in acute sixth nerve palsy, poor response in people with horizontal strabismus without binocular vision, similar or slightly
reduced achievement of successful ocular alignment in children with esotropia and potential increased achievement of successful ocular
alignment where surgery and botulinum toxin are combined. Further high quality trials using robust methodologies are required to
compare the clinical and cost effectiveness of various forms of botulinum toxin (e.g. Dysport, Xeomin, etc), to compare botulinum
toxin with and without adjuvant solutions and to compare botulinum toxin to alternative surgical interventions in strabismus cases
with and without potential for binocular vision.
P L A I N L A N G U A G E S U M M A R Y
Botulinum toxin for the treatment of strabismus
What is the aim of this review?
The aim of this Cochrane Review was to find out how well botulinum toxin works as a treatment for strabismus. Cochrane researchers
collected and analysed all relevant studies to answer this question and included six studies.
Key messages
The evidence as to the benefits and harms of using botulinum toxin for strabismus is uncertain.
What was studied in the review?
Strabismus occurs when the eyes are not aligned. Usually one eye turns inwards or outwards. Less frequently one eye turns upwards or
downwards. It is commonly known as “squint”.
Strabismus can lead to blurred vision or double vision. In children it can affect the long term development of vision in the affected eye.
There are many causes of strabismus. In most cases, there are problems with the muscles or nerves around the eye.
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Doctors can use botulinum toxin to stop individual muscles around the eye working for a while. This may help the eyes become more
aligned and may lead to less blurred or double vision. One problem with using botulinum toxin is that it can result in a droopy eyelid
(ptosis).
What are the main results of the review?
The review shows that:
• using botulinum toxin in children requiring primary treatment or retreatment for strabismus may make no difference, or slightly
reduce the chances of recovering correct alignment of the eyes compared with surgery (low-certainty evidence);
• using botulinum toxin in adults with strabismus may decrease the chances of recovering correct alignment of the eyes compared with
surgery (low-certainty evidence);
• people with sixth nerve palsy receiving botulinum toxin may have a similar or small increased chance of correct alignment of eyes
compared with no treatment (low-certainty evidence);
• the evidence on using botulinum toxin with surgery, compared with surgery alone, was very uncertain (very low-certainty evidence);
• ptosis occurred commonly in people receiving botulinum toxin in these studies. The number of people affected ranged from 1 in
10 to 1 in 2 people. Everyone recovered when treatment stopped. Ptosis occurred less frequently when treated with botulinum toxin
combined with sodium hyaluronate compared to botulinum toxin alone.
How up-to-date is this review?
The Cochrane researchers searched for studies that had been published up to 11 July 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Botulinum toxin versus surgery in adults and children with strabismus
Patient or population: adults and children with strabismus
Setting: hospital
Intervention: botulinum toxin
Comparison: surgery
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with surgery Risk with botulinum
toxin
Primary outcome: im-
proved ocular align-
ment ≤ 10 PD
Follow-up: median 6
months
Children
750 per 1000 683 per 1000
(533 to 870)
RR 0.91, (0.71 to 1.16) 102
(2 RCTs)
⊕⊕©©
low1,2
Downgraded 1 level for
risk of bias.
Downgraded 1 level for
imprecision.
Adults
750 per 1000 285 per 1000 (128 to
638)
RR 0.38 (0.17 to 0.85) 30
(1 RCT)
⊕⊕©©
low1,2
Downgraded 1 level for
risk of bias.
Downgraded 1 level for
imprecision.
Secondary outcome:
achievement of binocu-
lar single vision
616 per 1000 542 per 1000
(388 to 758)
RR 0.88
(0.63 to 1.23)
102
(2 RCTs)
⊕⊕©©
low1,2
Downgraded 1 level for
risk of bias.
Downgraded 1 level for
imprecision.
Secondary outcome:
achievement of ’sen-
sory’ fusion
616 per 1000 542 per 1000
(388 to 758)
RR 0.88
(0.63 to 1.23)
102
(2 RCTs)
⊕⊕©©
low1,2
Downgraded 1 level for
risk of bias.
Downgraded 1 level for
imprecision.
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Secondary outcome:
achievement of stere-
opsis
557 per 1000 479 per 1000
(328 to 696)
RR 0.86
(0.59 to 1.25)
102
(2 RCTs)
⊕⊕©©
low1,2
Downgraded 1 level for
risk of bias.
Downgraded 1 level for
imprecision.
Adverse events with bo-
tulinum toxin
Follow-up: median 6
months
Induced ptosis occurred in 20.8 to 41.66%across
trials.
Induced vert ical deviat ion occurred in 2.2 to 8.
3% across trials
All adverse events recovered within the follow-
up t ime period with no last ing adverse ef fect
- 102
(2 RCTs)
⊕⊕©©
low1,2
Downgraded 1 level for
risk of bias.
Downgraded 1 level for
imprecision.
* The risk in the intervent ion group (and its 95% CI) is based on the assumed risk in the comparison group and the relat ive ef fect of the intervent ion (and its 95% CI). We
derived the relat ive risk f rom the standardised mean dif ference for cont inuous data related to measured change in angle of deviat ion, measured in prism dioptres (PD) or
degrees. Relat ive risk for dichotomous data relat ing to achievement of binocular single vision as assessed by cover test, fusional vergence and stereoacuity.
Abbreviations: CI: conf idence interval; RR: risk rat io; OR: odds rat io; PD: prism dioptres; RCT: randomised controlled trial.
GRADE Working Group grades of evidence
High-certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate-certainty: we are moderately conf ident in the ef fect est imate. The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: our conf idence in the ef fect est imate is lim ited. The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: we have very lit t le conf idence in the ef fect est imate. The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1There was unclear sequence generat ion for 3 trials; the study invest igators were aware of pat ient randomisat ion in the
Tejedor 1998 and Tejedor 1999 trials.
2It was unclear f rom the results how many part icipants received unilateral or bilateral inject ions of botulinum toxin in the
Tejedor 1998 and Tejedor 1999 trials. Bilateral inject ion would have a greater ef fect on the angle of deviat ion than unilateral
inject ion.
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B A C K G R O U N D
Description of the condition
Strabismus is a deviation of the ocular alignment where one eye
turns, which may be intermittent or constant. It is a common con-
dition that occurs in up to 5% of the population and up to 50% in
special populations such as those with cerebral palsy (Adams 2005;
Donnelly 2005; Strömland 1993). In forms of strabismus that
are intermittent, binocular function (using both eyes as a pair) is
maintained with straight eyes for a variable proportion of the time.
In other forms there is a manifest deviation usually with a variable
degree of suppression of the deviating eye. Strabismus can be fur-
ther divided into esotropia (inturning deviation), exotropia (out-
turning deviation) or, less commonly, hypertropia (upturning de-
viation), hypotropia (downturning deviation) and cyclotropia (ro-
tatory deviation). Strabismus can be caused by a variety of insults
such as abnormal anatomical development of extraocular muscles
or the orbit, impaired neurological input to extraocular muscles,
uncorrected refractive error or hereditary factors. Sequelae to stra-
bismus can include blurring of vision, diplopia (double vision),
impaired depth (3-D) perception, and in younger children, am-
blyopia. Amblyopia is impaired vision in the deviating eye due to
the lack of correct stimulation of that eye and results in permanent
loss of vision if left untreated at a young age.
Description of the intervention
There are various treatments associated with strabismus. Primar-
ily treatment is directed at aligning the visual axes. Conservative
options include prisms to realign the visual axes and orthoptic ex-
ercises to promote and establish binocular control of ocular align-
ment where both eyes can subsequently work as a pair. Invasive
treatment options include surgery to permanently alter extraocular
muscle function and thus permanently change ocular alignment,
and botulinum toxin to individual extraocularmuscles. Scott 1980
first described this latter option, which temporarily paralyses the
extraocular muscle and results in a changed ocular alignment that
resolves over time (usually a two to three month time interval).
During this period of altered eye position, the visual axes may
adopt an ocular alignment that permits binocular single vision.
This is the ability to use both eyes as a pair so that both eyes con-
tribute to seeing a single image. This may persist or regress necessi-
tating further treatment. Botulinum toxin injection to extraocular
muscles is an alternative option that has become established in the
treatment of adults who have strabismus. Its use in children is less
well studied. It is perceived to be difficult to use in children due
to the need for sedation and complications following leakage of
the toxin into the levator palpebral superioris muscle (the muscle
responsible for elevating the eyelid) thus resulting in a droopy up-
per lid, known as ptosis (Rowe 2005).
Botulinum toxin has become recognised and accepted as both an
adjunct and alternative to strabismus surgery in many types of
strabismus (Bunting 2013; Campos 2000; Crouch 2006; Dawson
1999; Dawson 2004a; Dawson 2004b; Dawson 2005; Dawson
2012; Gardner 2013; Holmes 2001; Kerr 2001; Marsh 2003;
McNeer 2003; Ozkan 2006; Rayner 1999; Rowe 2004; Sabetti
2003; Spencer 1997; Tejedor 2001). Diagnostic uses of botulinum
toxin include investigation of postoperative diplopia (double vi-
sion), to detect whether fusion (which contributes to binocular
vision) is present preoperatively, to differentially diagnose between
a part and complete sixth nerve palsy, to aid in the prediction of
surgical results for incomitant deviations and to help in the inves-
tigation of a possible slipped muscle following surgery. In terms of
therapeutic uses botulinum toxin has been found useful in treat-
ing facial muscle spasm, strabismus, nystagmus, corneal ulcera-
tion and exposure keratitis to name a few. The therapeutic uses
of botulinum toxin for strabismus are to restore fusion in those
people with decompensating deviations, or those with a recover-
ing sixth nerve palsy, to align the cosmetic form of strabismus, to
aid surgical overcorrections and undercorrections and to aid in the
improvement of visual acuity by relieving oscillopsia (perception
of moving images) in cases of acquired nystagmus.
Other treatment options associated with strabismus include those
that address the sequelae of strabismus, such as occlusion therapy
for amblyopia which is a reduction in vision caused completely or
in part by the strabismus.
How the intervention might work
Botulinum toxin is a drug that is an exotoxin of the bacterium
Clostridium botulinum. Botulinum toxin type A is an injectable
neurotoxin. In order for muscles to contract, acetylcholine is re-
leased at the nerve-muscle junction. Acetylcholine binds to mus-
cle receptors causing a contraction. Botulinum toxin selectively
blocks the release of acetylcholine from the cholinergic synapses
found within a muscle, thereby blocking the nerve impulses and
preventing contraction of themuscle cells. Paralysis (which is tem-
porary) follows within days after injection of the toxin into the
extraocular muscle, and the toxin becomes fully effective within
three to seven days of the injection. The duration of paralysis is
dependent on the individual, but generally lasts for three months.
Once a muscle is paralysed, opposing muscles take on a greater
movement force and the eye position changes allowing the visual
axes to move into a straighter eye alignment.
Why it is important to do this review
Clear guidelines do not exist as to the recommended use of bo-
tulinum toxin for the treatment of strabismus particularly as so
many types of strabismus exist. Much of the published literature
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pertains to retrospective case series with varying treatment modal-
ities using different types of botulinum toxin (e.g. Dysport™ or
Botox™ or Prosign™ ) and different doses of the toxin.
O B J E C T I V E S
The primary objective was to examine the efficacy of botulinum
toxin therapy in the treatment of strabismus compared with al-
ternative conservative or surgical treatment options. This review
sought to ascertain those types of strabismus that particularly ben-
efit from the use of botulinum toxin as a treatment option (such as
small angle strabismus or strabismus with binocular potential, i.e.
the potential to use both eyes together as a pair). The secondary
objectives were to investigate the dose effect of botulinum toxin
and the complication rates associated with botulinum toxin.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) of treatment
using botulinum toxin for strabismus.
Types of participants
Participants with strabismus suitable for treatment with bo-
tulinum toxin to align the angle of deviation. This included adults
and children with no age limit.
Types of interventions
We considered trials in which botulinum toxin of all makes, e.g.
Dysport™, Botox™, Prosign™ were compared to the following:
• strabismus surgery;
• botulinum toxin alternatives;
• conservative therapy; orthoptic exercises, prisms, lens
therapy.
We made the following comparisons:
• single muscle versus multiple muscle injections of
botulinum toxin;
• botulinum toxin in combination with conservative
treatment versus conservative treatment alone;
• botulinum toxin versus other variant of botulinum toxin;
• botulinum toxin as an alternative to conservative treatment;
• botulinum toxin in combination with surgical treatment
versus surgical treatment alone;
• botulinum toxin as an alternative to surgical treatment;
• botulinum toxin versus observation (no treatment);
• strabismus types with binocular potential versus those
without binocular potential;
• small angle strabismus (less than 20 prism dioptres (PD))
versus large angle strabismus;
• level of dose of botulinum toxin and reported
complications at each dose.
Types of outcome measures
Primary outcomes
• improved ocular alignment as measured by a reduction in
the angle of deviation measured by prisms or the synoptophore.
We required a minimum of six months post-treatment follow up
for assessment of primary outcomes.
We classed outcomes as:
• success: full control of angle of deviation within 10 PD of
ortho (no deviation) with normal measures/ranges of binocular
single vision (simultaneous perception, motor fusional vergence
and stereopsis);
• satisfactory A: reduction in angle of deviation to within 20
PD of ortho with evidence of binocular single vision
(simultaneous perception, motor fusional vergence or
stereoacuity);
• satisfactory B: reduction in angle of deviation to within 20
PD of ortho without evidence of binocular single vision;
• fail: little or no change in angle of deviation and/or no
improvement in binocular single vision measures.
We analysed separately the change in angle of deviation (contin-
uous data) and the change in binocular single vision (categorical
data) followed by a composite measure of the two (ordinal data).
Secondary outcomes
Secondary outcome measures included:
• achievement of binocular single vision as assessed by cover
test, motor fusional vergences and stereoacuity.
Adverse outcomes
We considered the following adverse effects:
• induced ptosis;
• induced vertical deviation;
• subconjunctival haemorrhage;
• intolerable diplopia.
We categorized adverse effects as severe if they required further
treatment, or minor if no further treatment was required.
Also we recorded the complications noted within two weeks of
treatment in the included trials.
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Economic data
We included details of the cost of any treatments where data were
available.
Quality of life data
We considered anymeasure of participant or parent satisfaction re-
lating to improvement in appearance or improvement to lifestyle.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes and
Vision Trials Register) (2016, Issue 6), Ovid MEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations, Ovid
MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to July
2016), Embase (January 1980 to July 2016), Latin American
and Caribbean Literature on Health Sciences (LILACS) (Jan-
uary 1982 to July 2016), the ISRCTN registry (www.isrctn.com/
editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov),
and the World Health Organization (WHO) International Clini-
cal Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/
en). We did not use any date or language restrictions in the elec-
tronic searches for trials. We last searched the electronic databases
on 11 July 2016.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), Embase (Appendix 3),
LILACS (Appendix 4), ISRCTN (Appendix 5), ClinicalTrials.gov
(Appendix 6) and the WHO ICTRP (Appendix 7).
Searching other resources
We handsearched the British and Irish Orthoptic Journal, Aus-
tralian Orthoptic Journal, proceedings of the European Stra-
bismological Association (ESA), International Strabismologi-
cal Association (ISA) and International Orthoptic Association
(IOA) (www.liv.ac.uk/orthoptics/research/search.htm) and Amer-
ican Academy of Paediatric Ophthalmology and Strabismus meet-
ings (AAPOS). These resources were searched from 1980 to 11
July 2016. We contacted researchers who are active in the field for
information about further published or unpublished studies. We
used the Pediatric Ophthalmology and Strabismus mailbase in the
UK and USA. We screened the reference lists of publications.
Data collection and analysis
Selection of studies
Both review authors independently screened the titles and ab-
stracts obtained by the searches to establish whether they met the
criteria defined as include, exclude and unsure. Included papers
encompassed RCTs. Excluded papers encompassed case reports.
Unsure encompassed papers that comprised non-RCTs and case
series and a decision to include followed discussion between the
review authors. Arbitration from the Cochrane editorial base was
not required. Following this process, we obtained the full copies of
definitely or potentially relevant studies. Where information was
unclear we contacted the study authors. We documented the de-
tails of excluded studies in the ’Characteristics of excluded studies’
table. We constructed a PRISMA diagram to illustrate the study
selection process.
Data extraction and management
The two review authors independently extracted information re-
lating to outcomes using paper data collection forms developed
by Cochrane Eyes and Vision. We resolved discrepancies by dis-
cussion and entered data into Review Manager 5 (RevMan 5)
(RevMan 2014).
We extracted the following details from the included studies:
• methods: inclusion and exclusion criteria, follow-up period;
• participants: age, previous treatment, strabismus type;
• interventions: type of botulinum toxin used, dose measure,
number of injections;
• outcomes: ocular alignment and binocular function after a
minimum of six months;
• adverse events and quality of life measures.
We used the GRADE approach to interpret findings (Langendam
2013), and employed the GRADE profiler (GRADEpro) to im-
port data from RevMan 5 to create ’Summary of findings’ tables
(GRADEpro 2014). These tables provide outcome-specific infor-
mation concerning the overall certainty of evidence from studies
included in the comparisons, primary and secondary outcomes.
Assessment of risk of bias in included studies
We assessed study quality according to the methods set out in
Chapter 8 of theCochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011). We used the Cochrane tool for assessing
risk of bias. We assessed sequence generation, allocation conceal-
ment, masking (blinding) of participants, personnel and outcome
assessors, incomplete outcome data, selective outcome reporting
and other sources of bias. We made judgements for each domain
and graded each as either at low risk of bias, high risk of bias or
unclear.
We used theGRADE approach to interpret findings andGRADE-
pro to import data from RevMan 5.3 to create ’Summary of find-
ings’ tables. These tables provide outcome-specific information
concerning the overall certainty of evidence from RCTs included
in the comparison, the magnitude of effect of the interventions
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examined and the sum of available data on the outcomes we con-
sidered. For assessments of the overall certainty of evidence for
each outcome, we downgraded the evidence from high-certainty
by one level for each serious study limitation, e.g. risk of bias, im-
precision.
Measures of treatment effect
We considered the relative risk for dichotomous data relating to
binocular single vision and the standardized mean difference for
continuous data relating tomeasured change in angle of deviation.
Unit of analysis issues
We expected that studies may have consisted of parallel group
trials or cross-over trials. Where we found both in the search, we
considered these separately as botulinum toxin is known to have
a longer lasting effect than the average three months expected
for extraocular muscle function to fully recover. When analysing
secondary outcome measures, if possible we re-evaluated studies
that reported results ’per person’ to convert results to ’per injection’
as a more realistic indicator of prevalence.
Dealing with missing data
We contacted primary investigators/authors to obtain missing
data. We allowed a time period of three months for response. We
recorded non-response as missing data.
Assessment of heterogeneity
We assessed studies initially for heterogeneity using the Chi2 test.
However, considering the expected heterogeneity, we considered
the I2 statistic value to quantify inconsistency. We deemed meta-
analysis inappropriate on the basis of assessment of heterogeneity.
Therefore, we provided a descriptive summary of results.
Assessment of reporting biases
There were insufficient trials to examine publication bias using a
funnel plot.
Data synthesis
The results were heterogenous, hence we presented a descriptive
summary of results.
Subgroup analysis and investigation of heterogeneity
We evaluated studies for clinical heterogeneity (variability in the
participants or outcomes) andmethodological heterogeneity (vari-
ability in trial design and quality).
Sensitivity analysis
We did not perform a sensitivity analysis to assess the sensitivity of
the summary effect to the exclusion of trials assessed as inadequate
in terms of concealment of randomisation or those with missing
data or of questionable eligibility.
Methods for future updates
If trials become available in the future, we will include them in
this review using the methods for the primary review.
R E S U L T S
Description of studies
Results of the search
The electronic searches identified a total of 274 titles and abstracts.
We requested the full text for a total of eight studies.
An update search was done in December 2011. After deduplica-
tion the search identified a total of 53 references. The Cochrane
Information Specialist (CIS) (formerly known as Trials SearchCo-
ordinator) scanned the search results and removed 37 references
which were irrelevant to the scope of the review. We assessed the
remaining 16 references. Twelve references reported retrospective
or case cohort studies and we excluded them. We obtained full-
text copies of the remaining four references and extracted further
details.
Updates searches ran in July 2016 yielded a further 122 references
(Figure 1). After 27 we removed duplicates, the CIS screened the
remaining 95 records and removed 19 references which were not
relevant to the scope of the review. We screened the remaining
76 references and obtained the full-text reports of six references
for further assessment. We included two new studies (Chen 2013;
Minguini 2012), and excluded two studies (Etezad Razavi 2014:
Gursoy 2012). We identified two ongoing studies (Jain 2015;
PACTR201508001241218), and contacted the trial authors for
further information. We received responses from both trial teams,
who confirmed the ongoing recruitment to these studies.
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Figure 1. Study flow diagram.
10Botulinum toxin for the treatment of strabismus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
We included six trials and provided details below. Additional de-
tails can be found in the ’Characteristics of included studies’ table.
Tejedor 1999 randomised 55 strabismic children with infantile
esotropia receiving retreatment to two different treatment proce-
dures: reoperation or botulinum toxin (Botox™). This was a par-
allel RCT. The trial authors compared these groups to each other
for percentage of successful motor outcome less than or equal to
(
<
=) 8 prism dioptres (PD) and percentage change in deviation.
The latter was calculated as preoperative deviation - postoperative
deviation/preoperative deviation x 100%. Inclusion and exclusion
criteria were stipulated for the trial. Both groups were regarded as
comparable as similarities were present for both groups regarding
previous surgical procedures, mean age at initial surgery, average
time lapse between first and second treatment, angle of deviation,
refractive error and visual acuity measures. The trial achieved fol-
low-up to a minimum of 36 months.
Tejedor 1998 randomised 47 strabismic children with acquired
esotropia requiring retreatment to two different treatment pro-
cedures: reoperation or botulinum toxin (Botox™). This was a
parallel RCT. These groups were compared to each other for per-
centage net change in distance deviation, the percentage of par-
ticipants with successful motor outcome
<
= 8 PD and detectable
fusion and stereopsis. Percentage net change was calculated as pre-
operative deviation - postoperative deviation/preoperative devia-
tion x 100%. Inclusion and exclusion criteria were stipulated for
the trial. Both groups were regarded as homogenous as similari-
ties were present for both groups regarding previous surgical pro-
cedures, mean age at initial surgery, average time lapse between
first and second treatment, angle of deviation, refractive error and
follow-up. The trial achieved follow-up of 20 to 38 months.
Lee 1994 randomised 54 participants with acute unilateral sixth
nerve palsy into twogroups: those receiving botulinum toxin (Dys-
port™) to the isilateral medial rectus muscle and those observed
for recovery with no invasive treatment. This was a parallel RCT.
These groups were compared to each other for clinical diagnosis of
recovery. A full recovery was defined as completely normal ocular
rotations with full field of binocular single vision. Stable recov-
ery was defined as normal binocular single vision with a minor
asymptomatic abduction defect or a small asymptomatic vertical
deviation. Non recovery was defined as a persisting esotropia in
primary position with diplopia not controllable by normal ampli-
tudes of fusional vergence. Two control participants were excluded
and four were lost to follow-up. One botulinum toxin participant
was lost to follow-up. Follow-up ranged from four to 42 months.
Both groups were considered homogenous as gender, age range,
aetiology of sixth nerve palsy, duration of symptoms and laterality
of palsy were similar across both groups. The mean deviation of
control participants was 17.8 PD and for botulinum toxin partici-
pants was 28.6 PD. The difference in deviation across both groups
was significant (P = 0.02). Three of the 22 participants having
botulinum toxin injection had one repeat injection.
Carruthers 1990 randomised 30 adult participants with esotropia
or exotropia without binocular function requiring treatment by
two different procedures: botulinum toxin (Botox™) or ad-
justable suture surgery. This RCT had a cross-over design. These
groups were compared to each other for alignment of deviation
<
=
10 PD. In addition, percent net change was documented which
was defined as preoperative deviation - postoperative deviation/
preoperative deviation x 100%. Inclusion and exclusion criteria
were stipulated for the trial. Both groups had similar angles of
deviation and similar numbers of esotropia and exotropia angles.
The trial authors stated that five participants required further treat-
ment.However they did not provide any information as towhether
this constituted a cross-over of treatment options. A statement was
made that should cross-over occur, a minimum six month period
of follow-up would occur between treatments to allow for treat-
ment effect.
From the 2016 update, we included two trials. Minguini 2012
reported the results of the NCT01460355 trial previously found
in the 2011 search. They randomised 23 adult participants with
concomitant horizontal deviations (esotropia or exotropia) of less
than 50 PD requiring surgery. This was a double-masked RCT.
Group A received strabismus surgery plus botulinum toxin and
group B received strabismus surgery with placebo (hyaline solu-
tion). The groups were compared for net percentage change in
angle of deviation from pre-operative to 1 day through to six to
12 months postoperative in addition to numbers achieving align-
ment less than 8 PD. Inclusion and exclusion criteria were stipu-
lated for the trial. Both groups were regarded as homogenous as
similarities were present for age at surgery, angle of pre-operative
deviation, surgery ratio, best corrected visual acuity of either eye
and percentage of severe amblyopia. The trial achieved follow-up
to six to 12 months.
Chen 2013 randomised 47 participants with infantile esotropia
that required treatment with botulinum toxin as their first treat-
ment option. This was a two-group randomised trial. Group A
received botulinum toxin with sodium hyaluronate and group
B received botulinum toxin only. The groups were compared
for change in angle of deviation from pre-injection to 2 weeks,
3 months and 6 months post-injection in addition to numbers
achieving less than 10 PD. Inclusion and exclusion criteria were
stipulated for the trial. Both groups were regarded as homogenous
as similarities were present for age at treatment, gender and pre-
injection deviation. The trial achieved follow-up for 6 months.
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Excluded studies
We excluded four studies in 2009 (Cooper 1991; Mills 2004;
Sanjari 2008; Shallo-Hoffman 2006), three studies in 2011 (Li
2008; two reports by de AlbaCampomanes 2010), and two studies
in the 2016 update (Etezad Razavi 2014; Gursoy 2012).
For reasons of exclusion, see the ’Characteristics of excluded
studies’ table.
Risk of bias in included studies
We determined the risk of bias using the ’Risk of bias’ assessment
tool. This considers sequence generation, allocation concealment,
masking of participants, personnel and outcome assessors, incom-
plete outcome date, selective outcome reporting and other poten-
tial threats to validity (Figure 2; Figure 3). Our ’Risk of bias’ assess-
ment deemed the included trials to be low risk for concealment of
randomisation and we did not find incomplete data reporting.
Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 3. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Sequence generation was unclear in five trials (Carruthers 1990;
Chen 2013; Minguini 2012; Tejedor 1998; Tejedor 1999). It was
evident that randomisation had occurred but the included trials
did not state the method by which they did this. The latter four
trials were reported as having homogenous groups following ran-
domisation in terms of similarities for pre-treatment angle of de-
viation, age, gender, etc. Lee 1994 specified the use of a random
number table for sequence generation and thus we considered this
domain as at low risk of bias.
Allocation sequence was adequately generated inCarruthers 1990,
which constituted a low risk of bias as a research assistant allocated
participants separately, and in Minguini 2012 who reported allo-
cation as masked to surgeons. Allocation sequence was unclear or
inadequately generated in the remaining trials.
Blinding
Carruthers 1990 achieved adequate prevention of knowledge of
the allocated interventions in that the investigators andOrthoptist
were masked to participant randomisation when undertaking the
final evaluation of participants for outcome measures. Minguini
2012 achieved adequate masking as the trial authors reported
masking of both surgeons providing the treatment and outcome
assessors. The investigators were not masked to participant ran-
domisation in the remaining trials. However it is unlikely that the
absence of masking when evaluating final outcome of participants
would be biased as the outcome measures related to actual mea-
surements of eye position and responses to binocular assessments.
Incomplete outcome data
All studies adequately addressed incomplete outcome data, for
whichwe determined a low risk of bias. The trial authors accounted
for all participants throughout the trial and provided outcome data
for participants that completed the trial and provided information
on any participants that were lost to follow-up or excluded.
Selective reporting
We determined that all studies were free of suggestion of selective
outcome reporting in that the trial authors addressed the outcomes
specified in the methodology in the results of each study.
Other potential sources of bias
It was unclear whether any trial was completely free from poten-
tial sources of bias. Small numbers of participants were recruited
in both adult trials of horizontal strabismus and additionally, the
groups contained a mix of esotropic and exotropic participants
which reduced numbers for direct comparison further (Carruthers
1990; Minguini 2012). It was unclear whether Lee 1994 was
free from risk because of early discharge of some participants and
lack of long-term follow-up across all participants for comparison.
Three trials recruited low numbers of participants to the treatment
groups, which could impact on direct comparisons of each trial
group (Chen 2013; Tejedor 1998; Tejedor 1999).
Effects of interventions
See: Summary of findings for the main comparison Botulinum
toxin versus surgery; Summary of findings 2 Botulinum
toxin versus observation; Summary of findings 3 Surgery
with botulinum toxin versus surgery without botulinum toxin;
Summary of findings 4 Botulinum toxin with sodium
hyaluronate versus botulinum toxin without sodium hyaluronate
1. Botulinum toxin versus surgery
1.1 Primary outcome (improved ocular alignment
<
= 10 PD)
Tejedor 1999 defined a satisfactory outcome at one year follow-
up as
<
= 8 PD. This was achieved in 75% of the reoperation group
and 67.85% of the botulinum toxin group for treatment of in-
fantile esotropia. Percentage net change was 82.02% for the re-
operation group and 78.71% for the botulinum group. Tejedor
1998 defined a satisfactory outcome at one year follow-up as
<
=
8 PD. This was achieved in 75% of the reoperation group and
69.56% of the botulinum toxin group for treatment of childhood
strabismus. Percentage net change was 81.31% for the reoperation
group and 73.45% for the botulinum group. Carruthers 1990 re-
ported percentage net change in deviation at six months follow-
up. This was achieved in 92.7% in the surgery group and 50.59%
in the botulinum toxin group for treatment of adult strabismus.
A satisfactory outcome was defined as within 10 PD which was
achieved in 76.9% of the surgery group and 29.4% of the bo-
tulinum toxin group. This difference was noted as significant (P
= 0.027). ’Summary of findings’ table 1 shows a risk ratio (RR)
effect size of 0.79, 95% confidence interval (CI) 0.62 to 1.00; 132
participants; 3 studies; I2 statistic = 55% (Summary of findings
for the main comparison).We assessed the certainty of evidence as
low. We downgraded certainty by one level for risk of bias and by
one level for imprecision. Sequence generation was unclear; two
trials were aware of participant randomisation and it was unclear
for two trials how many had unilateral or bilateral injections of
botulinum toxin.
14Botulinum toxin for the treatment of strabismus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1.2 Secondary outcomes (achievement of binocular single
vision/sensory fusion/stereopsis)
Tejedor 1999 reported fusion (positive response with Worths four
light test andBagolini glasses test) and stereopsis (minimumof 480
seconds of arc) was present in 60.7% and 51.8% respectively of the
reoperation group and 57.1% and 48.1% respectively of the bo-
tulinum toxin group. There were no statistically significant differ-
ences between these outcomemeasures across both groups. Tejedor
1998 reported fusion (positive response with Worths four light
test) and stereopsis (minimum of 480 seconds of arc) was present
in 62.5% and 54.16% respectively of the reoperation group and
56.52% and 47.82% respectively of the botulinum toxin group.
There were no statistically significant differences between these
outcomemeasures across both groups. Analysis for achievement of
binocular single vision shows a RR effect size of 0.88, 95%CI 0.63
to 1.23; 102 participants; 2 studies; I2 statistic = 0%. We assessed
the certainty of evidence as low. We downgraded certainty by one
level for risk of bias and by one level for imprecision. Sequence
generation was unclear, two trials were aware of participant ran-
domisation and it was unclear for two trials how many had uni-
lateral or bilateral injections of botulinum toxin. Carruthers 1990
included participants with no binocular single vision. Thus sec-
ondary outcomes for achievement of binocular single vision and
fusion are not reported for this trial.
2. Botulinum toxin versus observation
2.1 Primary outcome (improved ocular alignment
<
=10PD)
Lee 1994 reported reduction in angle of deviation for acute onset
sixth nerve palsy within 10 PD in 80% of control participants
and 86% of botulinum toxin participants. The difference between
both groups was not statistically significant. ’Summary of findings’
table 2 shows a RR effect size of 1.19, 95% CI 0.96 to 1.48; 47
participants; 1 study (Summary of findings 2). We assessed the
certainty of evidence as low.We downgraded certainty by one level
for risk of bias. Investigators were aware of randomisation and it
was not possible tomask investigators or participants to allocation.
2.2 Secondary outcomes (achievement of binocular single
vision/sensory fusion/stereopsis)
Lee 1994 reported full recovery for sixth nerve palsy with achieve-
ment of binocular single vision in 80% of control participants
and 95.5% of botulinum toxin participants (see Table 1). The
difference between both groups was not statistically significant.
Analysis gave a RR effect size of 1.19, 95% CI 0.96 to 1.48; 47
participants; 1 study; I2 statistic = 0%. We assessed the certainty
of evidence as low. We downgraded certainty by one level for risk
of bias. Investigators were aware of randomisation and it was not
possible to mask investigators or participants to allocation.
3. Surgery with botulinum toxin versus surgery
without botulinum toxin
3.1 Primary outcome (improved ocular alignment
<
= 10PD)
Minguini 2012 reported net percentage change in deviation at six
to 12 months. A satisfactory change (angle within 20 PD) was
achieved in 79.4% of the surgery plus botulinum toxin group
compared to 68% in the surgery with hyaline solution group in
the treatment of adult large angle strabismus. Target alignment
was defined as within 8 PD. This was achieved in 33% of group
A and 18% in group B. ’Summary of findings’ table 3 shows a
RR effect size of 1.83, 95% CI 0.41 to 8.11; 23 participants; 1
study; I2 statistic = 0% (Summary of findings 3). We assessed
the certainty of evidence as low. We downgraded certainty by one
level for imprecision. It was unclear how sequence generation was
made.
4. Botulinum toxin with sodium hyaluronate versus
botulinum toxin without sodium hyaluronate
4.1 Primary outcome (improved ocular alignment
<
= 10PD)
Chen 2013 reported change in angle of deviation from pre-injec-
tion to six months post-injection. Good alignment was defined
as a deviation < 10 PD. This was achieved in 30.4% of group A
receiving botulinum toxin with sodium hyaluronate and 37.5% of
group B receiving botulinum toxin only for treatment of infantile
esotropia, with no significant difference between groups. ’Sum-
mary of findings’ table 4 shows a RR effect size of 0.81, 95% CI
0.36 to 1.82; 47 participants; 1 study; I2 statistic = 0% (Summary
of findings 4). We assessed the certainty of evidence as low. We
downgraded certainty by one level for risk of bias in relation to
allocation concealment, performance bias and detection bias. Se-
quence generation was not specified.
5. Adverse events with use of botulinum toxin
Tejedor 1999 reported transient ptosis in 37.03% of participants
and transient vertical deviation in 18.51%. Tejedor 1998 reported
transient ptosis in 34.78%of participants and transient vertical de-
viation in 17.39%. Carruthers 1990 did not report complications
from use of botulinum toxin. Lee 1994 reported two cases with
transient ptosis and four cases with transient vertical deviation
with a total complication rate of 24% per injection and 27% per
participant. Minguini 2012 reported ptosis in 41.6% and vertical
deviation in 8.3% of group A with no complications described in
group B. Chen 2013 reported complications of ptosis occurred in
2.2% of group A and 20.8% of group B which was significant (P
= 0.008). Complications of vertical deviation occurred in 2.2%
of group A and 2.1% of group B which was not significantly dif-
ferent. Analysis from five RCTs found transient ptosis occurring
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in 9 to 41.66% of participants and vertical deviation occurring
in 8.3 to 18.51% of participants (Table 2). We assessed the cer-
tainty of evidence as low. We downgraded certainty by one level
for imprecision because of mixed populations reducing numbers
for comparison. Sequence generation was unclear for all but one
trial (Lee 1994).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Botulinum toxin versus observat ion in adults with strabismus
Patient or population: adults with strabismus due to acute onset sixth nerve palsy
Setting: hospital
Intervention: botulinum toxin
Comparison: observat ion
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with surgery Risk with botulinum
toxin
Primary outcome: im-
proved ocular align-
ment ≤ 10 PD
Follow-up: median 6
months
800 per 1000 952 per 1000
(768 to 1000)
RR 1.19
(0.96 to 1.48)
47
(1 RCT)
⊕⊕©©
low1,2
Downgraded 1 level for
risk of bias.
Downgraded 1 level for
imprecision.
Secondary outcome:
achievement of binocu-
lar single vision
800 per 1000 952 per 1000
(768 to 1000)
RR 1.19
(0.96 to 1.48)
47
(1 RCT)
⊕⊕©©
low1,2
Downgraded 1 level for
risk of bias.
Downgraded 1 level for
imprecision.
Secondary outcome:
achievement of ’sen-
sory’ fusion
- - - 0 - -
Secondary outcome:
achievement of stere-
opsis
- - - 0 - -
Adverse events with bo-
tulinum toxin
Follow-up: median 6
months3
Induced ptosis occurred in 9%.
Induced vert ical deviat ion occurred in 18%.
All adverse events recovered within the follow-
up t ime period with no last ing adverse ef fect
- 47
(1 RCT)
⊕⊕©©
low1,2
Downgraded 1 level for
risk of bias.
Downgraded 1 level for
imprecision.1
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* The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI). Relat ive
risk was derived f rom standardised mean dif ference for cont inuous data related to measured change in angle of deviat ion - measured in prism dioptres (PD) or degrees.
Relat ive risk for dichotomous data relat ing to achievement of binocular single vision as assessed by cover test, fusional vergence and stereoacuity.
Abbreviations: CI: conf idence interval; RR: risk rat io; OR: odds rat io; RCT: randomised controlled trial; PD: prism dioptres.
GRADE Working Group grades of evidence
High-certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate-certainty: we are moderately conf ident in the ef fect est imate. The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: our conf idence in the ef fect est imate is lim ited. The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: we have very lit t le conf idence in the ef fect est imate. The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1The study invest igators were aware of randomisat ion.
2It was not possible to mask the study invest igators or part icipants to treatment allocat ion.
3All part icipants in study had acute onset sixth nerve palsy.
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Surgery with botulinum toxin versus surgery without botulinum toxin in adults with strabismus
Patient or population: adults with strabismus
Setting: hospital
Intervention: surgery with botulinum toxin
Comparison: surgery without botulinum toxin
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with surgery Risk with botulinum
toxin
Primary outcome: im-
proved ocular align-
ment ≤ 10 PD
Follow-up: median 6
months
182 per 1000 333 per 1000
(75 to 1000)
RR 1.83
(0.41 to 8.11)
23
(1 RCT)
⊕⊕©©
very low1,2,3
Downgraded 1 level for
risk of bias.
Downgraded 2 levels
for imprecision.
Secondary outcome:
achievement of binocu-
lar single vision
- - - - - -
Secondary outcome:
achievement of ’sen-
sory’ fusion
- - - - - -
Secondary outcome:
achievement of stere-
opsis
- - - - - -
Adverse events with bo-
tulinum toxin
Follow-up: median 6
months
Induced ptosis occurred in 37.03%.
Induced vert ical deviat ion occurred in 18.51%.
All adverse events recovered within the follow-
up t ime period with no last ing adverse ef fect
- 23
(1 RCT)
⊕⊕©©
low1,2,3
Downgraded 1 level for
risk of bias.
Downgraded 1 level for
imprecision.
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* The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI). We
derived the relat ive risk f rom the standardised mean dif ference for cont inuous data related to measured change in angle of deviat ion, measured in prism dioptres (PD) or
degrees. Relat ive risk for dichotomous data relat ing to achievement of binocular single vision was assessed by cover test, fusional vergence and stereoacuity.
Abbreviations: CI: conf idence interval; RR: risk rat io; OR: odds rat io; PD: prism dioptres; RCT: randomised controlled trial.
GRADE Working Group grades of evidence
High-certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate-certainty: we are moderately conf ident in the ef fect est imate. The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: our conf idence in the ef fect est imate is lim ited. The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: we have very lit t le conf idence in the ef fect est imate. The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Unclear if part icipants blinded to treatment allocat ion.
2Unclear how the sequence generat ion was made as it was unspecif ied.
3Mixed populat ion of esotropia and exotropia part icipants, which reduced the numbers of part icipants for comparison.
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Botulinum toxin with sodium hyaluronate versus botulinum toxin without sodium hyaluronate in children with strabismus
Patient or population: children with strabismus
Setting: hospital
Intervention: botulinum toxin with sodium hyaluronate
Comparison: botulinum toxin without sodium hyaluronate
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with surgery Risk with botulinum
toxin
Primary outcome: im-
proved ocular align-
ment ≤ 10 PD
Follow-up: median 6
months
375 per 1000 304 per 1000
(135 to 683)
RR 0.81
(0.36 to 1.82)
47
(1 RCT)
⊕⊕©©
low1,2
Downgraded 1 level for
risk of bias.
Downgraded 1 level for
imprecision.
Secondary outcome:
achievement of binocu-
lar single vision
- - - - - -
Secondary outcome:
achievement of ’sen-
sory’ fusion
- - - - - -
Secondary outcome:
achievement of stere-
opsis
- - - - - -
Adverse events with bo-
tulinum toxin
Follow-up: median 6
months
Induced ptosis occurred in 23.4% overall; 2.2% in
group A and 20.8% in group B
Induced vert ical deviat ion occurred in 17.39%.
Ptosis occurred less f requent ly when treated
with botulinum toxin combined with sodium
hyaluronate compared to botulinum toxin alone
- 47
(1 RCT)
⊕⊕©©
low1,2
Downgraded 1 level for
risk of bias.
Downgraded 1 level for
imprecision.
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All adverse events recovered within the follow-
up t ime period with no last ing adverse ef fect
* The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI). We
derived the relat ive risk f rom the standardised mean dif ference for cont inuous data related to measured change in angle of deviat ion, measured in prism dioptres (PD) or
degrees. Relat ive risk for dichotomous data relat ing to achievement of binocular single vision was assessed by cover test, fusional vergence and stereoacuity.
Abbreviations: CI: conf idence interval; RR: risk rat io; OR: odds rat io; PD: prism dioptres; RCT: randomised controlled trial.
GRADE Working Group grades of evidence
High-certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate-certainty: we are moderately conf ident in the ef fect est imate. The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: our conf idence in the ef fect est imate is lim ited. The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: we have very lit t le conf idence in the ef fect est imate. The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Sequence generat ion was not specif ied for this trial; it was unclear how part icipants were randomised.
2The study invest igators were aware of part icipat ion randomisat ion and were not masked to allocat ion.
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D I S C U S S I O N
We included six randomised controlled trials in this review which
compared botulinum toxin (Dysport™or Botox™or Prosign™)
to either strabismus surgery or conservative treatment or adju-
vant solution. The strabismus conditions treated in five trials
were unlikely to alter with time without treatment (Carruthers
1990; Chen 2013; Minguini 2012; Tejedor 1998; Tejedor 1999),
whereas the ocular motility condition in the remaining trial was
likely to change spontaneously with time (Lee 1994). Risk calcu-
lations in anticipated absolute effects across the different types of
interventions in these trials varied greatly. This is reflective of the
heterogenous groups that comprised different intervention com-
parisons and different types of ocular motility conditions.
From these trials we were able to make the following comparisons
based on the information available in the trial papers: botulinum
toxin as an alternative to conservative treatment; botulinum toxin
as an alternative to surgical treatment; surgery with or without ad-
juvant botulinum toxin, botulinum toxin with or without an ad-
juvant solution; strabismus types with binocular potential versus
those without binocular potential; and reported complications.
Notably, for this last comparison, we were unable to evaluate oc-
currence of complications across a range of different doses due to
insufficient data in the trial results.
We found the certainty of evidence for all outcomes to be of mod-
erate- or low-certainty primarily due to risk of bias and imprecise
results because of lack of clarity in reporting trial methodology.
We were able to address the primary outcome of improved ocular
alignment as measured by a reduction in angle of deviation in all
six trials. However, the main limiting factor for analysis was that
results were not comparable across the trials due to different con-
ditions being targeted by each trial plus the different types and
doses of botulinum toxin used in each trial. We were able to ad-
dress the primary classification outcome (success, satisfactory A,
satisfactory B or fail) in one trial only (Lee 1994), as two trials pro-
vided the information for change in angle of deviation and binoc-
ular outcome separately (Tejedor 1998; Tejedor 1999), and there
was no binocular outcome for the participants in the remaining
three trials (Carruthers 1990; Chen 2013; Minguini 2012).
Secondary outcomes included achievement of binocular single vi-
sion and documentation of adverse effects. We determined the
former outcome in three trials (Lee 1994; Tejedor 1998; Tejedor
1999), but again the results were not comparable due to differences
in target condition and use of botulinum toxin. Four trials used
Botox™ (Carruthers 1990; Chen 2013; Tejedor 1998; Tejedor
1999), one trial used Dysport™ (Lee 1994), and one trial used
Prosign™ (Minguini 2012), with varying doses utilised for each
drug type.Hence the reported adverse effects were not comparable
between trials. However, one trial compared the same type of bo-
tulinum toxin (Botox™) with one group receiving Botox™ plus
sodium hyaluronate and the second group receiving Botox™ only
(Chen 2013). This trial showed a significant increase in ptosis as
an adverse event in the Botox™ only group.
We were not able to obtain information on the cost of treatment
or on measures of participant or parent satisfaction relating to
treatment options and effectiveness of botulinum toxin.
Summary of main results
There is a large body of literature on the subject of the use of bo-
tulinum toxin for the treatment of strabismus. Strabismus encom-
passes many types including esotropia, exotropia, vertical devia-
tions, concomitant, acute onset and incomitant strabismus, plus
strabismus with or without binocular vision. Therefore there are
many variables that contribute to outcome after treatment. The
literature on botulinum toxin consists predominantly of retrospec-
tive studies, cohort studies and case series, which are useful for
describing the use of botulinum toxin in varying strabismus types
but do not aid the establishment of reliable guidelines for the use
of botulinum toxin as a treatment intervention or enable interpre-
tation of treatment efficacy.
Improved ocular alignment
This was defined as measurement of a reduction in the angle
of deviation by prisms or the synoptophore. All included trials
achieved a reduction in angle of deviation using botulinum toxin
to within 10 PD, ranging from 29.4% (Carruthers 1990), 30.4%
(Chen 2013), 33.33% (Minguini 2012), 66.66% (Tejedor 1998),
69.56% (Tejedor 1999), to 95.5% (Lee 1994). The lowest per-
centage was achieved in a strabismus condition that did not have
binocular potential and this was significantly different from the re-
duction in angle of deviation achieved by surgery in this trial. The
highest percentage was achieved in an ocular motility condition in
which all participants had binocular potential. The reduction in
angle of deviation achieved using botulinum toxin in three trials
where participants had binocular potential showed no significant
difference to the reduction in angle of deviation achieved by stra-
bismus surgery (Tejedor 1998; Tejedor 1999), or by observation/
conservative treatment (Lee 1994).
Percentage net change in deviation was also calculated for five
trials. For RCTs that compared botulinum toxin to reoperation,
the percentage net change was not significant across both groups
in which the strabismus type included presence of binocular vi-
sion as an outcome measure (Tejedor 1998; Tejedor 1999). For
one trial where the strabismus type specifically excluded binocu-
lar vision, the percentage net change was significantly lower for
the botulinum toxin group in comparison to the adjustable suture
surgery group (Carruthers 1990). For a second trial in which the
strabismus type had no demonstrable binocular vision, the net per-
centage change was greater for the surgery group combined with
botulinum toxin compared to surgery alone (Minguini 2012). For
the trial that compared botulinum toxin to observation for recent
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onset sixth nerve palsy, the change in ocular alignment was similar
for both groups (Lee 1994).
Effect size of risk ratio (RR) varied from0.79 (botulinum toxin ver-
sus surgery) to 0.81 (botulinum toxin with versus without sodium
hyaluronate) to 1.19 (botulinum toxin versus observation) to 1.83
(surgery with or without botulinum toxin).
Outcomes
A successful outcome was classed as full control of the ocular devi-
ation with a measurement within 10 PD and with normal binoc-
ular single vision. This was achieved in 86% (botulinum toxin)
and 80% (controls) respectively in participants from the trial of
sixth nerve palsies (Lee 1994; Analysis 1.3). There was insufficient
information provided in the trials by as outcomes for change in
deviation and binocular vision were provided separately and not
integrated (Tejedor 1998; Tejedor 1999; Analysis 2.1; Analysis
2.3). Carruthers 1990 and Minguini 2012 excluded participants
with binocular vision potential and Chen 2013 did not report any
information on binocular potential for their participants. Thus we
could not apply our classification of successful outcome to these
trials. Achievement of binocular vision was further classified in
this review as satisfactory A (angle within 20 PD with binocular
vision), satisfactory B (angle within 20 PD without binocular vi-
sion) and fail (little or no change in angle and without binocular
vision).We were unable to use these classifications in Tejedor 1998
and Tejedor 1999 as measurements were not provided for the par-
ticipants that failed to obtain a successful outcome plus outcomes
for binocular vision were stated separately to outcomes for angle
of deviation. Lee 1994 reported a successful outcome in 80% and
95.5%, satisfactory A outcome in 12% and 0% and a failed out-
come for 8% and 4.5% for non treatment and botulinum toxin
treatment groups respectively (Analysis 2.2). The participants re-
cruited in Carruthers 1990, Minguini 2012 and Chen 2013 had
no reported binocular function and thus would not fall in the sat-
isfactory A classification. We were unable to classify participants
from the trial by Carruthers 1990 to satisfactory B or fail cate-
gories with reliability as deviations were stated as greater than 10
PD but with no ranges provided for these unsuccessful partici-
pants. 23.1% of the surgery group and 70.6% of the botulinum
toxin group were either satisfactory B or fail classifications. Five
of 30 participants were unsatisfied with their exotropia deviation
and required further treatment. The range of final responses for
all participants having botulinum toxin spread from 0 to 100%
change in deviation (0 would be classed as a fail) and for par-
ticipants having surgery, the spread was 67% to 100% change.
Minguini 2012 reported 5/12 participants in group A and 6/11
participants in group B as achieving satisfactory B with angles of
deviation of less than 20 PD, and 2/12 participants in group A
plus 3/11 participants in group B achieving a fail with angles of
deviation greater than 20 PD. Chen 2013 reported no data on
angles of deviation greater than 10 PD at follow-up.
Adverse outcomes
Such outcomes may include induced transient ptosis, vertical de-
viation, subconjunctival haemorrhage and intolerable diplopia.
The included trials reported transient ptosis in 23.4%, 37.03%,
9%, 34.78%, 41.6% and 20.8% respectively and reported tran-
sient vertical deviation in 17.39%, 18.51%, 18%, 8.3% and 2.2%
respectively for occurrence of adverse outcomes per participant
(Chen 2013; Lee 1994; Minguini 2012; Tejedor 1998; Tejedor
1999). The overall complication rate ranged from 27% to 55.54%
in these trials. Lee 1994 also reported the occurrence of adverse
outcomes per injection as three participants underwent repeat bo-
tulinum toxin injection. The overall complication rate was 24%
per injection. No other adverse outcomes were reported follow-
ing the use of botulinum toxin in these trials. The duration of
transient ptosis or vertical deviation was not stated in any of these
trials. There were no adverse outcomes stated in any of the three
trials relating to the strabismus surgery.
Overall completeness and applicability of
evidence
Six RCTs of low-certainty evidence met the inclusion criteria of
this review. Each trial related to a different type of strabismus or
ocular motility condition; namely infantile esotropia, acute on-
set esotropia, sixth nerve palsy and horizontal strabismus without
binocular vision. Hence this precluded a meta-analysis. It was not
possible to ascertain information on dose effect as the six included
trials used different types of botulinum toxin (Botox™versusDys-
port™ versus Prosign™) and different dosages. In addition, we
were unable to obtain information on the cost of treatment or on
measures of participant or parent satisfaction relating to treatment
options and effectiveness. However, we described the outcome of
treatment in each trial and ascertained the occurrence of adverse
events in relation to the use of botulinum toxin.
Quality of the evidence
Downgrading of certainty of evidence was primarily related to risk
of bias and/or imprecision. There was a lack of clarity on sequence
generation or an inability to mask investigators and participants
to allocation.
Potential biases in the review process
As far as we are aware we have minimised potential biases in
the review process. We have followed the methods set out in the
published protocol. The only amendment was to add in a sum-
mary of findings table and GRADE assessment as required by
new Cochrane standards. To our knowledge, all potentially eli-
gible studies were included - we implemeted an extensive search
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strategy with independent checks by both authors of the search
results. See Figure 2 and Figure 3.
We obtained mixed results when we evaluated the included trials
for risk of bias. One study was at low risk of bias in relation to
sequence generation (Lee 1994). This was unclear for the other
included trials. Two trials had a low risk of bias in relation to
allocation concealment (Carruthers 1990; Minguini 2012). This
was not achieved by the other trials. We considered all trials as at
low risk of bias for the domains of masking, incomplete outcome
bias and selective outcome reporting. However, we judged all trials
as unclear in relation to the potential risk of other sources of bias.
This was due to small participant numbers in each trial group for
five trials (Carruthers 1990; Chen 2013; Minguini 2012; Tejedor
1998; Tejedor 1999), and due to early discharge of participants
who had shown recovery before a six-month follow up period with
lack of long-term follow up comparison across both groups (Lee
1994).
Agreements and disagreements with other
studies or reviews
Our results are in general agreement with published observation
studies of the use of botulinum toxin for the treatment of stra-
bismus. Notably, these observation studies consider a variety of
strabismus or ocular motility conditions (Crouch 2006; Dawson
2004b; Dawson 2005; Marsh 2003; Rayner 1999; Scott 1980)
and each trial in this review also addressed a different strabismus
or ocular motility condition. In addition, the included trials used
different types and doses of botulinum toxin - similar to other ob-
servation studies published in the literature (Crouch 2006; Rayner
1999). It was thus not possible to compare these studies for agree-
ment or disagreement of results. Botulinum toxin shows no dif-
ference in response in comparison to surgery in participants who
required retreatment for acquired esotropia or infantile esotropia
and in whom there was potential for binocular vision. Botulinum
enhanced the effect of strabismus surgery in participants with stra-
bismuswithout binocular potential. Botulinum toxin had a poorer
effect in comparison to surgery in participants with strabismus
without binocular potential. It showed no difference compared
to no treatment in acute sixth nerve palsy and thus was deemed
to have no prophylactic effect in this condition. The occurrence
of adverse effects was similar to those reported in previous obser-
vation studies, particularly ptosis and induced vertical deviations
(Crouch 2006; Marsh 2003; Rayner 1999).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Due to the limited number of RCTs identified in this review, the
low-certainty of evidence and the variations in the conditions being
treated, it has not been possible to address fully the outcomes of
this review.
Without considering the type of strabismus or ocular motility be-
ing treated, botulinum toxin has been shown to reduce the angle of
deviation by amounts comparable to surgical intervention. How-
ever, the type of strabismus is important when considering the
secondary outcome of binocular vision. In horizontal strabismus
types without potential for binocular vision there was a poorer
treatment effect reported with botulinum toxin treatment com-
pared to strabismus surgery. However, for horizontal strabismus
typeswithout potential for binocular vision, therewas an improved
treatment effect reported with combined strabismus surgery and
botulinum toxin in comparison to surgery alone. In those strabis-
mus types where there is potential for binocular vision, such as
acute onset esotropia, sixth nerve palsy and infantile esotropia, bo-
tulinum toxin has been shown to achieve little difference in levels
of binocular vision compared to surgery. Therefore on the basis of
these studies botulinum toxin can be considered as an indepen-
dent treatment option.
In terms of adverse events there was difficulty in evaluating the
studies because of the varying doses and types of botulinum toxin
used. For trials using comparable types and/or doses of Botox™
the prevalence of reported adverse events were similar with ap-
proximately one third of cases developing transient ptosis and one
fifth developing transient vertical deviation.
Implications for research
There is clearly a need for good quality trials to be conducted
utilising botulinum toxin across the varying types of strabismus
in order to improve the evidence base for the use of botulinum
toxin as an independent management option. Standardisation is
of utmost importance taking into consideration the types of bo-
tulinum toxin available and the dosages used as these aspects are
not comparable. The presence or absence of binocular vision is
also an important variable to consider in future trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Carruthers 1990
Methods Surgery versus botulinum toxin in adult strabismus without binocular function
Allocation: masked and randomised sequence
Masking: achieved for provider and outcome
Exclusions: 0
Losses: 0
Study design: RCT with cross-over of treatment if unsatisfactory result at 6 months
Participants Country: Canada
Randomised number: 30 participants (30 eyes)
Recruitment dates: Fall 1985 to 1988 i.e. 2.5 years.
Strabismus type: 20 exotropia (8 male and 12 female), 10 esotropia (4 male, 6 female)
Botulinim toxin (BT); 12 exotropia, 5 esotropia
Surgery; 8 exotropia, 5 esotropia
Angle of deviation; 60 prism dioptres (PD) of exotropia to 50 PD of esotropia
BT; 12 to 35 PD of esotropia (average 25.4 PD), 16 to 60 PD of exotropia (average 33.
7 PD)
Surgery; 12 to 50 PD of esotropia (average 31.4 PD), 16 to 50 PD of exotropia (average
32.6 PD)
Age > 16 years
BT; mean 33 years (17 to 58 years)
Surgery; mean 35 years (16 to 60 years)
Sex:
BT; 8 male, 9 female
Surgery; 4 male, 9 female
Inclusion criteria: angle greater than 10 PD, no binocular vision, > 16 years, attended
follow-up appointments
Exclusion criteria: evidence of binocular vision
Repeat injections: undertaken in 9 participants
Interventions Treatment:
Surgery; Unilateral 2 muscle or surgery with adjustable on recessed muscle
BT; 5 units Botox™. Participants offered repeat botulinum toxin (BT) injection if, at any
time during 6 weeks following initial injection, the angle of deviation was not reduced
below 10 PD. Re-injections provided twice for 5 participants, 3 times for 3 participants
and four times for 1 participant
Choice of eye for intervention: Side of intervention eye not specified
Duration: minimum 6 months follow-up. Participants were followed up at 1 day, 6
weeks, 3 months and 6 months postoperatively
Outcomes Reduction in angle to < 10 PD:
Surgery; outcome achieved in 29.4% (5 participants)
BT; outcome achieved in 76.9% (10 participants)
% net change (preoperative deviation - postoperative deviation / preoperative deviation
x 100%):
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Carruthers 1990 (Continued)
Surgery; 92.7% average change in deviation at 6 months
BT; 50.59% average change in deviation at 6 months
Choice of eye: Analysis of outcomes based on binocular measurement of change in angle
of deviation and reported adverse events monocularly in the intervention eye
Notes No complications reported
No costs reported
No quality of life indicators reported
Funding: support from the British Columbia Health Care Research Foundation
Declarations of interest: the Smith-Kettlewell Instititue of Vision Sciences supplied the
needle for the trial. Alan Scott from the Smith-Kettlewell Institute supplied Oculinum
Trial registration number: not specified.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised but how this
was done was not stated
Allocation concealment (selection bias) Low risk Participants were randomised by a research
assistant
Blinding (performance bias and detection
bias)
Investigators
Low risk Investigators were masked (blinded) to par-
ticipant allocation for final outcome assess-
ment
Blinding (performance bias and detection
bias)
Participants
Unclear risk It was not possible to mask participants to
the different treatment options. This was
not judged to affect outcome measures
Blinding (performance bias and detection
bias)
Personnel
Low risk Investigators and the orthoptist were
masked to participant randomisation when
undertaking the final evaluation of partici-
pants for outcome measures
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for in the
results with provision of outcome data
Selective reporting (reporting bias) Low risk The specified outcomes in the methodol-
ogy were reported in the results, i.e. per-
centage net change in deviation and success
with final deviation < 10 PD
Other bias Unclear risk Small numbers of participants across each
trial group. Mix of esotropia and exotropia
participants further reduce numbers for
comparison as these may respond differ-
ently to use of BT or surgery
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Chen 2013
Methods Botulinum toxin with sodium hyaluronate versus botulinum toxin alone for infantile
esotropia
Allocation: unknown
Masking: unsure for outcome
Exclusions: 0
Losses: 0
Study design: parallel RCT
Participants Country: China
Randomised number: 47 participants (94 eyes) = 23 in group A, 24 in group B
Dates of recruitment: February 2008 to May 2011
Inclusion criteria: infantile esotropia with onset before 6months of age. Botulinum toxin
(BT) chosen as first line treatment
Exclusion criteria: orthotropic after refractive correction, Previous strabismus surgery,
Systemic diseases, Allergy to drugs
Age: 12 to 81 months at time of injection. Group A = 38.0 ±17.5. Group B = 35.8 ±20.
7
Sex: 22 male, 25 female. Group A = 43.5% male. Group B = 50% male
Angle of deviation: Group A = 35.0 ±15.7 PD, group B = 33.9 ±16.7 PD
Follow-up to 6 months.
Interventions Group A:
Bilateral injection of 0.05 mL Botox™ (2.5 to 3.75 units) with sodium hyaluronate
(SH) in the absence of electromyography. Mix of BT solution with SH at volume ratio
of 1:3
Group B:
Bilateral injection of 0.03 mL Botox™ (2.5 to 3.75 units) without sodium hyaluronate
in the absence of electromyography
Doses of 2.5 units for deviations < 30 PD. Doses of 3.75 units for deviations > 30 PD
Choice of eye for intervention: All received bilateral injections at 1 time point only
Outcomes Change in angle of deviation:
Group A = 30.4% achievement of angle < 10 PD.
Group B = 37.5% achievement of angle < 10 PD.
Presence of binocular vision not reported.
Choice of eye: analysis of outcomes based on binocular measurement of change in angle
of deviation and reported adverse events monocularly for each intervention eye
Notes Ptosis: 2.2% in group A versus 20.8% in group B
Vertical deviation: 2.2% in group A versus 2.1% in group B.
No report of duration of transient adverse events.
10 with monocular amblyopia, 5 with primary inferior oblique overaction, 3 with dis-
sociated vertical deviation (DVD), 1 with inferior oblique overaction and DVD
No costs reported.
No quality of life indicators reported.
Funding: support from Guangdong Provincial Scientific Technological Research Fund
Declaration of interests: the authors declared no interests.
Trial registration number: not specified.
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Chen 2013 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised but how this
was done was not stated. The two groups
were evaluated as being homogenous
Allocation concealment (selection bias) High risk Investigators were aware of participant ran-
domisation.
Blinding (performance bias and detection
bias)
Investigators
High risk Investigators did not appear to be masked
to the different treatment options
Blinding (performance bias and detection
bias)
Participants
Unclear risk Patinets could be masked to the treatment
allocation but it was not stated of they were
informed of treatment group or not
Blinding (performance bias and detection
bias)
Personnel
High risk All preparations for treatment were made
by the same treating physician
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for in the
results with provision of outcome data
Selective reporting (reporting bias) Low risk The specified outcomes in the methodol-
ogy were reported in the results, i.e. change
in angle of deviation and reporting of ad-
verse events
Other bias Unclear risk Small number of participants across each
trial group.
Lee 1994
Methods Botulinum toxin versus observation for acute onset sixth cranial nerve palsy
Allocation: random number table
Masking: not achieved
Exclusions: 2 due to change in diagnosis
Losses: 5 lost to follow-up
Study design: parallel RCT
Participants Country: UK
Randomised number: 54 participants (54 eyes) - 22 in botulinum toxin (BT) group and
25 in control group
Dates of recruitment: August 1989 to August 1992
Age:
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Lee 1994 (Continued)
Controls; mean 61 years (24 to 86 years)
BT; mean 63 years (24 to 83 years)
Sex:
Controls; 12 males, 13 females
BT; 13 males, 9 females
Inclusion criteria: Hospital emergency department walk-in
Exclusion criteria: change in diagnosis
Duration of symptoms:
Controls;
<
= 1 week in 17,
<
= 2 weeks in 6, 3 weeks in 1 and 4 weeks in 1
BT;
<
= 1 week in 7,
<
= 2 weeks in 9,
<
= 3 weeks in 5 and 6 weeks in 1
Angle of deviation:
Controls; primary position at distance fixation fixing with nonparetic eye; mean 17.8
PD (4 to 40 PD)
BT; primary position at distance fixation fixing with nonparetic eye; mean 28.6 PD (6
to 70 PD)
Repeat injections; undertaken in 3 participants
Interventions Treatment:
BT; 2.5 units Dysport™ to ipsilateral medial rectus muscle
3 participants had a second injection when first injection was inadequate
Control: observation
Duration: 4 to 42 months. Participants were followed up at 1 week, 6 weeks and 4
months as a minimum
Discharged at 4 months if fully recovered
Choice of eye for intervention: Ipsilateral eye to the cranial nerve palsy - conventional
choice
Outcomes Full recovery: normal range of eye movement and full field binocular single vision
BT; 95.5% (20 participants)
Controls; 80% (16 participants)
Stable BSV: normal BSV with minor asymptomatic abduction deficit
BT; 4.5% (1 participant)
Controls; 16% (4 participants)
No recovery: persistent esotropia in primary gaze with diplopia
BT; 4.5% (1 participant) becoming 13.6% (3 participants) due to recurrence of the sixth
nerve palsy over long term follow-up
Controls; 20% (5 participants)
Choice of eye: analysis of outcomes based on binocular measurement of change in angle
of deviation and reported adverse events monocularly in the intervention eye
Notes Overall complication rate of 24% per injection (6/25) and 27% per participant (6/22)
2 cases of ptosis
4 cases of vertical deviation
No report of duration of transient adverse events
No costs reported
No quality of life indicators reported
Funding: none specified.
Declarations of interest: none specified.
Trial registration number: none specified.
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Lee 1994 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table was used
Allocation concealment (selection bias) High risk Investigators were aware of participant ran-
domisation
Blinding (performance bias and detection
bias)
Investigators
Unclear risk Investigators did not appear to be masked
to the different treatment options
Blinding (performance bias and detection
bias)
Participants
Unclear risk It was not possible to mask participants to
the different treatment options. This plus
investigator knowledge of participant allo-
cation to treatment group was not judged
to affect outcome measures
Blinding (performance bias and detection
bias)
Personnel
High risk Investigators appeared aware of the differ-
ent treatment options
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants lost to follow-up or excluded
were accounted for along with participants
followed to designated follow-up periods.
Despite loss of participants, a similar num-
ber of participants existed for each group
in the trial
Selective reporting (reporting bias) Low risk The specified outcomes in the methodol-
ogy were reported in the results, i.e. full
recovery, stable BSV and non recovery of
palsy
Other bias Unclear risk Follow-up varied upwards from 4 months
post onset of palsy
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Minguini 2012
Methods Surgery with botulinum toxin versus surgery alone for large angle adult strabismus
Allocation: unknown
Masking: achieved for provider and outcome
Exclusions: 0
Losses: 2 from group A did not attend final follow-up visit
Study design: parallel RCT with double-masked assessment
Participants Country: Brazil
Randomised number: 23 participants (23 eyes) = 12 in group A, 114 in group B
Inclusion criteria: adults > 18 years of age with large angle (>50 PD) concomitant
horizontal strabismus (esotropia or exotropia)
Exclusion criteria: previous strabismus surgery, neurological or systemic disease, oblique
extraocular muscle over or under action, vertical deviation, dissociated vertical deviation
(DVD), paretic or restrictive strabismus
Age: Group A = 34.3 ± 6.4. Group B = 28.8 ± 9.8
Sex: Group A = 6 females and 6 males. Group B = 6 females and 5 males
Angle of deviation: Group A = 65.8 ±14.9 PD with 6 exotropia and 6 esotropia, group
B = 60.0 ±16.9 PD with 7 exotropia and 4 esotropia
Follow-up to 6 months.
Interventions Group A:
Strabismus surgery plus injection of 5 units of botulinum toxin (Prosign™) in 0.1 mL
of hyaline solution
Group B:
Strabismus surgery plus injection of 0.1 mL of hyaline solution
Choice of eye for intervention: non-fixing eye - conventional choice
Outcomes Percent net change in angle of deviation from pre-operative to 6 to 12 months postop-
erative:
Group A = 33.33% achievement of angle < 10 PD.
Group B = 18.1% achievement of angle < 10 PD.
Presence of binocular vision not reported.
Choice of eye: analysis of outcomes based on binocular measurement of change in angle
of deviation and reported adverse events monocularly in the intervention eye
Notes Ptosis: 41.6% in group A versus 0% in group B
Vertical deviation: 8.3% in group A versus 0% in group B.
No report of duration of transient adverse events.
No costs reported.
No quality of life indicators reported.
Funding: none specified.
Declarations of interest: the authors declared no commercial or proprietary interests
Trial registration number: none specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Minguini 2012 (Continued)
Random sequence generation (selection
bias)
Unclear risk Participants were randomised but how this
was done was not stated
Allocation concealment (selection bias) Low risk Surgeons were masked to treatment alloca-
tion.
Blinding (performance bias and detection
bias)
Investigators
Low risk Double-masked assessment with surgeons
and assessors masked to allocation
Blinding (performance bias and detection
bias)
Participants
Unclear risk Possible to mask participants to treatment
allocation but not specified as to whether
this was done
Blinding (performance bias and detection
bias)
Personnel
Low risk Double-masked assessment with surgeons
and assessors masked to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for in the
results with provision of outcome date
Selective reporting (reporting bias) Low risk The specified outcomes in the methodol-
ogy were reported in the results, i.e. per-
centage net change in deviation and adverse
events
Other bias Unclear risk Small numbers of participants across each
trial group. Mix of esotropia and ex-
otropia participants which may further re-
duce numbers for comparison as these may
respond differently to use of surgery with/
without botulinum toxin
Tejedor 1998
Methods Surgery versus botulinum toxin for childhood strabismus
Allocation: unknown
Masking: unsure for outcome
Exclusions: 0
Losses: 0
Study design: parallel RCT
Participants Country: Spain
Randomisednumber: 47participants - 24 in surgery group (38 eyes) and23 inbotulinum
toxin (BT) group (number of eyes unclear)
Dates of recruitment: 1989 to 1994
Age at treatment in RCT: not specified
Age at initial surgery:
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Tejedor 1998 (Continued)
Surgery; mean 3.56 years (SD 1.53)
BT; mean 3.29 years (SD 1.28)
Time between initial and secondary treatment:
Surgery; mean 1.5 years (SD 0.98)
BT; mean 0.99 years (0.84)
Sex: not specified
Inclusion criteria: adequate; < 11 years old, 1 previous operation, 10 PD angle
Exclusion criteria: adequate; Near/Distance disparity, Vertical deviation > 4 PD, nystag-
mus, A/V pattern, amblyopia > 4 lines
Pretreatment angle of deviation:
Surgery; mean 21.32 PD (SD 18.84) at near fixation and mean 18.58 PD (SD 18.52)
at distance fixation
BT; mean 22.16 PD (SD 16.83) at near fixation and mean 18.69 PD (SD 16.56) at
distance fixation
Interventions Treatment:
Sx for esotropia; recession/resection or re-recession or bilateral resection
Sx for exotropia; bilateral recession
BT: 3 to 10 units Botox™
Follow-up after treatment:
Surgery; mean 2.9 years (SD 0.81)
BT; mean 2.7 years (SD 0.42)
Minimum 1 year follow-up
Repeat BT injections; none reported
Choice of eye for intervention:
Surgery; unilateral surgery if previous surgery was unilateral (10 participants), bilateral
surgery if previous surgery was bilateral (14 participants)
BT; unilateral injection if dose required < 5 units, bilateral injection if dose required > 5
units
Outcomes Reduction in angle to < 8 PD:
Surgery; outcome achieved in 75% (18 participants)
BT; outcome achieved in 69.56% (16 participants)
Presence of binocular vision:
Surgery; outcome achieved in 62.5% (15 participants)
BT; outcome achieved in 56.52% (13 participants)
Reduction in angle of deviation and presence of binocular vision were considered sepa-
rately
Net % change (preoperative deviation - postoperative deviation / preoperative deviation
x 100%):
Surgery; mean 81.31% change in deviation at 1 year
BT; mean 73.45% change in deviation at 1 year
Choice of eye: Analysis of outcomes based on binocular measurement of change in angle
of deviation and reported adverse events monocularly in each intervention eye
Notes Overall complication rate of 52.17% (12/23) per participant
Ptosis; 34.78% (8/23)
Vertical; 17.39% (4/23)
No report of duration of transient adverse events
No costs reported
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Tejedor 1998 (Continued)
No quality of life indicators reported
Funding: none specified
Declarations of interest: none specified
Trial registration number: none specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised but how this
was done was not stated. The two groups
were evaluated as being homogenous
Allocation concealment (selection bias) High risk Investigators were aware of participant ran-
domisation
Blinding (performance bias and detection
bias)
Investigators
High risk Investigators did not appear to be masked
to the different treatment options
Blinding (performance bias and detection
bias)
Participants
Unclear risk It was not possible to mask participants to
the different treatment options. This plus
investigator knowledge of participant allo-
cation to treatment group was not judged
to affect outcome measures
Blinding (performance bias and detection
bias)
Personnel
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for in the
results with provision of outcome data
Selective reporting (reporting bias) Low risk The specified outcomes in the methodol-
ogy were reported in the results, i.e. per-
centage mean change in deviation, success-
ful motor outcome with final deviation <
8 PD and successful sensory outcome with
positive fusion and stereo response
Other bias Unclear risk Small numbers of participants across each
trial group
38Botulinum toxin for the treatment of strabismus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tejedor 1999
Methods Allocation: unclear
Masking: unsure for outcome
Exclusions: 0
Losses: 0
Study design: parallel RCT
Participants Country: Spain
Randomised number: 55 participants - 28 in surgery group (56 eyes) and 27 in BT
group (number of eyes unclear)
Dates of recruitment: 1990 to 1994
Age at retreatment in RCT; not specified
Age at initial surgery:
Surgery; mean 15.33 months (SD 3.31)
BT; mean 14.25 months (SD 3.12)
Time between initial and secondary treatment:
Surgery; mean 6.25 months (SD 1.60)
BT; mean 5.50 months (1.23)
Sex:
Surgery; 13 females, 15 males
BT; 12 females, 15 males
Inclusion criteria: adequate; esotropia < 6months, no accommodative element, retreated
within 12 months
Exclusion criteria: adequate; accom element present, vertical > 4 PD, medical or neuro
disease
Pretreatment angle of deviation:
Surgery; mean 28.87 PD (SD 12.41) at near fixation and mean 25.40 PD (SD 11.35)
at distance fixation
BT; mean 24.12 PD (SD 16.02) at near fixation and mean 20.27 PD (SD 15.15) at
distance fixation
Interventions Treatment:
Surgery for esotropia; bilateral LR resection ± bilateral MR recession
Surgery for exotropia; bilateral LR recession or MR advancement
BT: 3 to 12.5 units Botox™
Follow-up after retreatment:
Surgery; mean 3.75 years (SD 0.12)
BT; mean 3.5 years (SD 0.21)
Minimum 6 month follow-up
Repeat BT injections: none reported
Choice of eye for intervention:
Surgery; all had bilateral surgery as previous surgery was bilateral (28 participants, 56
eyes)
BT; unilateral injection if dose required < 5 units, bilateral injection if dose required > 5
units
Outcomes Reduction in angle to < 8 PD:
Surgery; outcome achieved in 75% (21 participants)
BT; outcome achieved in 66.66% (18 participants)
Presence of binocular vision:
Surgery; outcome achieved in 60.71% (17 participants)
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Tejedor 1999 (Continued)
BT; outcome achieved in 51.85% (14 participants)
Reduction in angle of deviation and presence of binocular vision were considered sepa-
rately
Net % change (preoperative deviation - postoperative deviation / preoperative deviation
x 100%):
Surgery; mean 82.02% change in deviation at 6 months
BT; mean 78.71% change in deviation at 6 months
Choice of eye: analysis of outcomes based on binocular measurement of change in angle
of deviation and reported adverse events monocularly in each intervention eye
Notes Overall complication rate of 55.54% (15/27) per participant
Ptosis; 37.03% (10/27)
Vertical; 18.51% (5/27)
No report of duration of transient adverse events
No costs reported
No quality of life indicators reported
Funding: none specified
Declarations of interest: the authors declare no conflicts of interest
Trial registration number: none specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised but how this
was done was not stated. The two groups
were evaluated as being homogenous
Allocation concealment (selection bias) High risk Investigators were aware of participant ran-
domisation
Blinding (performance bias and detection
bias)
Investigators
Unclear risk Investigators did not appear to be masked
to the different treatment options
Blinding (performance bias and detection
bias)
Participants
Low risk It was not possible to mask participants to
the different treatment options. This plus
investigator knowledge of participant allo-
cation to treatment group was not judged
to affect outcome measures
Blinding (performance bias and detection
bias)
Personnel
Unclear risk This was not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for in the
results with provision of outcome data
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Tejedor 1999 (Continued)
Selective reporting (reporting bias) Low risk The specified outcomes in the methodol-
ogy were reported in the results, i.e. per-
centage mean change in deviation, success-
ful motor outcome with final deviation <
8 PD and successful sensory outcome with
positive fusion and stereo response
Other bias Unclear risk Small numbers of participants across each
trial group
Abbreviations: A&E: accident and emergency department; AV: A or V pattern; Accom: accommodation; BSV: binocular single vision;
BT: botulinum toxin; BV: binocular vision; F: female; F/U: follow-up; LR: lateral rectus muscle;M: male; MR: medial rectus muscle;
N/D: near/distance; PD: prism dioptres; RCT: randomised controlled trial; Sx: surgery.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cooper 1991 The paper consisted of the preliminary findings for the paper by Lee 1994 documented in the ’Included
studies’
de Alba Campomanes 2010 Prospective, non-randomised comparative study and not a randomised controlled trial (RCT)
Etezad Razavi 2014 Prospective, non-randomised comparative study and not a RCT
Gursoy 2012 Retrospective review of botulinum toxin versus strabismus surgery outcomes for treatment of esotropia
Li 2008 Prospective, non-randomised clinical study and not a RCT
Mills 2004 Review article and not a RCT in itself
Sanjari 2008 Case series and not a RCT
Shallo-Hoffman 2006 Study of the influence of adaptation in people with chronic sixth nerve palsy having botulinum toxin.
Results not applicable to the objectives of this review
Abbreviations: RCT: randomised controlled trial.
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Characteristics of ongoing studies [ordered by study ID]
Jain 2015
Trial name or title Intraoperative botulinum toxin in large angle strabismus
Methods Prospective randomised case control study
Participants Large angle strabismus
Interventions Surgery alone versus surgery with botulinum toxin
Outcomes Postoperative reduction in angle of deviation plus adverse events from botulinum toxin
Starting date August 2012
Contact information Chief investigator: Mr S Jain, Royal Free Hospital, London
Notes -
PACTR201508001241218
Trial name or title Botulinum toxin in childhood strabismus
Methods Prospective randomised parallel arm controlled trial
Participants Children aged 6 months to 6 years with esotropia
Interventions Botulinum toxin versus bilateral medial rectus muscle recession surgery
Outcomes Degree of alignment; cost effectiveness comparison; adverse events
Starting date February 2015
Contact information Chief investigator: Mr I Mayet, St John Eye Hospital, Soweto, Johannesburg
Notes -
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D A T A A N D A N A L Y S E S
Comparison 1. Botulinum toxin versus surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome - improved
ocular alignment ≤ 10 PD
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Children 2 102 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.71, 1.16]
1.2 Adults 1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.17, 0.85]
2 Secondary outcome -
achievement of binocular single
vision
2 102 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.63, 1.23]
3 Secondary outcome -
achievement of ’sensory’ fusion
2 102 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.63, 1.23]
4 Secondary outcome -
achievement of stereopsis
2 102 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.59, 1.25]
Comparison 2. Botulinum toxin versus observation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome - improvement
of ocular alignment ≤ 10 PD
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Secondary outcome -
classification
Other data No numeric data
3 Secondary outcome -
achievement of binocular single
vision
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 3. Surgery with botulinum toxin versus surgery without botulinum toxin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome - improved
ocular alignment ≤ 10 PD
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Comparison 4. Botulinum toxin with sodium hyaluronate versus botulinum toxin without sodium hyaluronate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome - improved
ocular alignment ≤ 10 PD
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Botulinum toxin versus surgery, Outcome 1 Primary outcome - improved
ocular alignment ≤ 10 PD.
Review: Botulinum toxin for the treatment of strabismus
Comparison: 1 Botulinum toxin versus surgery
Outcome: 1 Primary outcome - improved ocular alignment≤ 10 PD
Study or subgroup Botulinum toxin Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Children
Tejedor 1998 16/23 18/24 46.1 % 0.93 [ 0.65, 1.32 ]
Tejedor 1999 18/27 21/28 53.9 % 0.89 [ 0.63, 1.25 ]
Subtotal (95% CI) 50 52 100.0 % 0.91 [ 0.71, 1.16 ]
Total events: 34 (Botulinum toxin), 39 (Surgery)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
2 Adults
Carruthers 1990 5/17 10/13 100.0 % 0.38 [ 0.17, 0.85 ]
Subtotal (95% CI) 17 13 100.0 % 0.38 [ 0.17, 0.85 ]
Total events: 5 (Botulinum toxin), 10 (Surgery)
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Chi2 = 4.14, df = 1 (P = 0.04), I2 =76%
0.1 0.2 0.5 1 2 5 10
Favours surgery Favours botulinum toxin
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Analysis 1.2. Comparison 1 Botulinum toxin versus surgery, Outcome 2 Secondary outcome - achievement
of binocular single vision.
Review: Botulinum toxin for the treatment of strabismus
Comparison: 1 Botulinum toxin versus surgery
Outcome: 2 Secondary outcome - achievement of binocular single vision
Study or subgroup Botulinum toxin Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tejedor 1998 13/23 15/24 46.8 % 0.90 [ 0.56, 1.45 ]
Tejedor 1999 14/27 17/28 53.2 % 0.85 [ 0.53, 1.37 ]
Total (95% CI) 50 52 100.0 % 0.88 [ 0.63, 1.23 ]
Total events: 27 (Botulinum toxin), 32 (Surgery)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours surgery Favours botulinum toxin
Analysis 1.3. Comparison 1 Botulinum toxin versus surgery, Outcome 3 Secondary outcome - achievement
of ’sensory’ fusion.
Review: Botulinum toxin for the treatment of strabismus
Comparison: 1 Botulinum toxin versus surgery
Outcome: 3 Secondary outcome - achievement of ’sensory’ fusion
Study or subgroup Botulinum toxin Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tejedor 1998 13/23 15/24 46.8 % 0.90 [ 0.56, 1.45 ]
Tejedor 1999 14/27 17/28 53.2 % 0.85 [ 0.53, 1.37 ]
Total (95% CI) 50 52 100.0 % 0.88 [ 0.63, 1.23 ]
Total events: 27 (Botulinum toxin), 32 (Surgery)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours surgery Favours botulinum toxin
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Analysis 1.4. Comparison 1 Botulinum toxin versus surgery, Outcome 4 Secondary outcome - achievement
of stereopsis.
Review: Botulinum toxin for the treatment of strabismus
Comparison: 1 Botulinum toxin versus surgery
Outcome: 4 Secondary outcome - achievement of stereopsis
Study or subgroup Botulinum toxin Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tejedor 1998 11/23 13/24 44.7 % 0.88 [ 0.50, 1.55 ]
Tejedor 1999 13/27 16/28 55.3 % 0.84 [ 0.51, 1.40 ]
Total (95% CI) 50 52 100.0 % 0.86 [ 0.59, 1.25 ]
Total events: 24 (Botulinum toxin), 29 (Surgery)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours surgery Favours botulinum toxin
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Analysis 2.1. Comparison 2 Botulinum toxin versus observation, Outcome 1 Primary outcome -
improvement of ocular alignment ≤ 10 PD.
Review: Botulinum toxin for the treatment of strabismus
Comparison: 2 Botulinum toxin versus observation
Outcome: 1 Primary outcome - improvement of ocular alignment≤ 10 PD
Study or subgroup Botulinum toxin Observation Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lee 1994 21/22 20/25 1.19 [ 0.96, 1.48 ]
0.1 0.2 0.5 1 2 5 10
Favours observation Favours botulinum toxin
Analysis 2.2. Comparison 2 Botulinum toxin versus observation, Outcome 2 Secondary outcome -
classification.
Secondary outcome - classification
Study Total
participants
Success Satisfactory A Satisfactory B Fail Data
Lee 1994 47
22 (Botulinum
toxin)
25 (Observation/
Conservative)
21 (95.5%)
20 (80%)
3 (12%) 1 (4.5%)
2 (8%)
Ordinal
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Analysis 2.3. Comparison 2 Botulinum toxin versus observation, Outcome 3 Secondary outcome -
achievement of binocular single vision.
Review: Botulinum toxin for the treatment of strabismus
Comparison: 2 Botulinum toxin versus observation
Outcome: 3 Secondary outcome - achievement of binocular single vision
Study or subgroup Botulinum toxin Observation Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lee 1994 21/22 20/25 1.19 [ 0.96, 1.48 ]
0.1 0.2 0.5 1 2 5 10
Favours observation Favours botulinum toxin
Analysis 3.1. Comparison 3 Surgery with botulinum toxin versus surgery without botulinum toxin,
Outcome 1 Primary outcome - improved ocular alignment ≤ 10 PD.
Review: Botulinum toxin for the treatment of strabismus
Comparison: 3 Surgery with botulinum toxin versus surgery without botulinum toxin
Outcome: 1 Primary outcome - improved ocular alignment≤ 10 PD
Study or subgroup Surgery with BT Surgery without BT Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Minguini 2012 4/12 2/11 1.83 [ 0.41, 8.11 ]
0.1 0.2 0.5 1 2 5 10
Favours surgery alone Favours surgery + BT]
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Analysis 4.1. Comparison 4 Botulinum toxin with sodium hyaluronate versus botulinum toxin without
sodium hyaluronate, Outcome 1 Primary outcome - improved ocular alignment ≤ 10 PD.
Review: Botulinum toxin for the treatment of strabismus
Comparison: 4 Botulinum toxin with sodium hyaluronate versus botulinum toxin without sodium hyaluronate
Outcome: 1 Primary outcome - improved ocular alignment≤ 10 PD
Study or subgroup BT with SH BT without SH Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chen 2013 7/23 9/24 0.81 [ 0.36, 1.82 ]
0.1 0.2 0.5 1 2 5 10
Favours BT without SH Favours BT with SH
A D D I T I O N A L T A B L E S
Table 1. Botulinum toxin versus observation
Study ID Total
participants
Success Satisfactory A Satisfactory B Fail Data
Lee 1994 22 botulinum
toxin
25 observation/
conservative
47 in total
21 (95.5%)
20 (80%)
3 (12%) - 1 (4.5%)
2 (8%)
Ordinal
Table 2. Adverse events with botulinum toxin
Study ID Total partici-
pants (Botox)
Total partici-
pants (Dysp-
port)
Total partici-
pants
(Prosign)
Ptosis (per
patient)
Vertical devi-
ation (per pa-
tient)
Ptosis (per
injection)
Vertical devi-
ation (per in-
jection)
Chen 2013 47 - - 23.4% (11/
47)
4.25% (2/47) - -
Lee 1994 - 22 - 9% (2/22) 18% (4/22) 8% (2/25) 16% (4/25)
Minguini
2012
- - 12 41.66% (5/
12)
8.3% (1/12) - -
Tejedor 1998 23 - - 34.78% (8/
23)
17.39% (4/
23)
- -
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Table 2. Adverse events with botulinum toxin (Continued)
Tejedor 1999 27 - - 37.03% (10/
27)
18.51% (5/
27)
- -
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Strabismus
#2 strabism* or squint*
#3 esotropi*
#4 exotropi*
#5 hypertropi*
#6 hypotropi*
#7 cyclotropi*
#8 heterophori*
#9 esophori*
#10 exophori*
#11 hyperphori*
#12 hypophori*
#13 cyclophori*
#14 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13)
#15 MeSH descriptor Botulinum Toxins
#16 botulin* toxin*
#17 botox*
#18 dysport*
#19 MeSH descriptor Clostridium botulinum
#20 clostridium botulin*
#21 (#15 OR #16 OR #17 OR #18 OR #19 OR #20)
#22 (#14 AND #21)
Appendix 2. MEDLINE (Ovid) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomized).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
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13. exp strabismus/
14. (strabism$ or squint$).tw.
15. esotropi$.tw.
16. exotropi$.tw.
17. hypertropi$.tw.
18. hypotropi$.tw.
19. cyclotropi$.tw.
20. heterophori$.tw.
21. esophori$.tw.
22. exophori$.tw.
23. hyperphori$.tw.
24. hypophori$.tw.
25. cyclophor$.tw.
26. or/13-25
27. exp botulinum toxins/
28. botulin$ toxin$.tw.
29. botox$.tw.
30. dysport$.tw.
31. exp clostridium botulinum/
32. clostridium botulin$.tw.
33. or/27-32
34. 26 and 33
35. 12 and 34
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase (Ovid) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
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26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp strabismus/
34. (strabism$ or squint$).tw.
35. esotropi$.tw.
36. exotropi$.tw.
37. hypertropi$.tw.
38. hypotropi$.tw.
39. cyclotropi$.tw.
40. heterophori$.tw.
41. esophori$.tw.
42. exophori$.tw.
43. hyperphori$.tw.
44. hypophori$.tw.
45. cyclophor$.tw.
46. or/33-45
47. botulinum toxin/
48. botulin$ toxin$.tw.
49. botox$.tw.
50. dysport$.tw.
51. Botulinum toxin A/
52. exp clostridium botulinum/
53. clostridium botulin$.tw.
54. or/47-53
55. 46 and 54
56. 32 and 55
Appendix 4. LILACS search strategy
botulin$ or botox$ and strabism$
Appendix 5. ISRCTN search strategy
botulinum and strabismus
Appendix 6. ClinicalTrials.gov search strategy
Strabismus AND (Botox OR Botulinum)
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Appendix 7. WHO ICTRP search strategy
(Condition) Strabismus AND (Intervention) Botox OR Botulinum
WH A T ’ S N E W
Last assessed as up-to-date: 11 July 2016.
Date Event Description
11 July 2016 New search has been performed Issue 3, 2017: electronic searches were updated
11 July 2016 New citation required but conclusions have not changed Issue 3, 2017: two new trials were included in the review
(Chen 2013; Minguini 2012). Inclusion of GRADE
H I S T O R Y
Protocol first published: Issue 2, 2007
Review first published: Issue 2, 2009
Date Event Description
7 December 2011 New citation required but conclusions have not
changed
Issue 2, 2012: electronic searches were updated but no
new trials were identified
7 December 2011 New search has been performed Issue 2, 2012: the ’Risk of bias’ assessments were up-
dated according to new Cochrane methodology
14 October 2008 Amended Converted to new review format.
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from papers, provided additional data about papers, obtained and screened data on unpublished studies, entered data into RevMan 5
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FR and CN updated the review.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We used the ’Risk of bias’ tool to assess the risk of bias of the included studies and the GRADE approach to assess the certainty of
the evidence for each outcome. Given the developments in the production and use of botulinum toxin since the original protocol, for
interventions in the current review, we added comparisons for the following:
• comparison of botulinum toxin alternatives, i.e. different brands of botulinum toxin compared to each other;
• comparison of botulinum toxin with and without added substances, e.g. sodium hyaluronate, saline.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Abducens Nerve Diseases [∗drug therapy]; Botulinum Toxins, Type A [∗therapeutic use]; Neuromuscular Agents [∗therapeutic use];
Randomized Controlled Trials as Topic; Strabismus [∗drug therapy; surgery]
MeSH check words
Adult; Child; Humans
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